Home / Lacosamide / Czechia
CZ ATC N03AX18 · updated 2 Nov 2026
Lacosamide shortage in Czechia
Is there a Lacosamide shortage in Czechia?
Yes. As of 2 Nov 2026, 12 Lacosamide products are reported short in Czechia, the first since 30 Jan 2024. The company estimate for the return is 20 Nov 2026 (latest 1 Oct 2027). Main reason: commercial decision or withdrawal.
Also short in Canada, Italy, Spain, Sweden, Australia. All countries.
Affected products in Czechia
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CZ | LACOSAMIDE ACCORD 10MG/ML 10MG/ML INF SOL 1X20ML | Accord Healthcare S.L.U., Barcelona | 30 Jan 2024 | 4 Jan 2027 | Manufacturing problem Výrobní důvody |
| CZ | KANILAD 100MG 100MG TBL FLM 28 | Medochemie Ltd., Limassol | 30 Jan 2026 | 1 Oct 2027 | Commercial decision or withdrawal Obchodní/marketingové důvody |
| CZ | KANILAD 150MG 150MG TBL FLM 28 | Medochemie Ltd., Limassol | 30 Jan 2026 | 1 Oct 2027 | Commercial decision or withdrawal Obchodní/marketingové důvody |
| CZ | KANILAD 200MG 200MG TBL FLM 28 | Medochemie Ltd., Limassol | 30 Jan 2026 | 1 Oct 2027 | Commercial decision or withdrawal Obchodní/marketingové důvody |
| CZ | LACOSAMIDE ACCORD 150MG 150MG TBL FLM 56 | Accord Healthcare S.L.U., Barcelona | 30 Mar 2026 | 4 Jan 2027 | Manufacturing problem Výrobní důvody |
| CZ | LACOSAMIDE GLENMARK 100MG 100MG TBL FLM 84 | Glenmark Pharmaceuticals s.r.o., Praha | 29 May 2026 | 1 Oct 2027 | Commercial decision or withdrawal Obchodní/marketingové důvody |
| CZ | LACOSAMIDE GLENMARK 150MG 150MG TBL FLM 84 | Glenmark Pharmaceuticals s.r.o., Praha | 29 May 2026 | 1 Oct 2027 | Commercial decision or withdrawal Obchodní/marketingové důvody |
| CZ | LACOSAMIDE GLENMARK 200MG 200MG TBL FLM 84 | Glenmark Pharmaceuticals s.r.o., Praha | 29 May 2026 | 1 Oct 2027 | Commercial decision or withdrawal Obchodní/marketingové důvody |
| CZ | LACOSAMIDE GLENMARK 50MG 50MG TBL FLM 56 | Glenmark Pharmaceuticals s.r.o., Praha | 29 May 2026 | 1 Oct 2027 | Commercial decision or withdrawal Obchodní/marketingové důvody |
| CZ | KANILAD 100MG 100MG TBL FLM 56 | Medochemie Ltd., Limassol | 13 Jul 2026 | not given | Manufacturing problem Výrobní důvody |
| CZ | KANILAD 50MG 50MG TBL FLM 14 | Medochemie Ltd., Limassol | 20 Oct 2026 | 30 Nov 2026 | Commercial decision or withdrawal Obchodní/marketingové důvody |
| CZ | LACOSAMIDE FRESENIUS KABI 10MG/ML 10MG/ML INF SOL 5X20ML | Fresenius Kabi s.r.o., Praha | 2 Nov 2026 | 20 Nov 2026 | Distribution or logistics Kapacitní/distribuční důvody |
Source
SÚKL (State Institute for Drug Control), market reports. Official list. Products whose latest market report is a supply interruption; one row per SÚKL code.